Simcere Pharmaceutical Group Limited (SIMCERE PHARMA) filed its Monthly Return for the period ended 31 March 2026, showing that the company’s equity structure remained unchanged during the month.

Issued Share Capital • Outstanding ordinary shares stood at 2.60 billion (2,595.70 million) with zero treasury shares, identical to the February 2026 closing balance. • No new shares were issued, cancelled, or transferred in March. • An earlier buy-back of 12.83 million shares (repurchased on 13 June 2025) remains pending formal cancellation; however, it did not affect the March share count.

Equity Incentive Update • Under the amended Restricted Share Unit (RSU) Scheme approved on 15 June 2023, 2.17 million RSUs were granted on 26 March 2026. • The RSU pool authorises up to 235.20 million ordinary shares for future issuance, but none were vested or issued during the reporting month.

Public Float Confirmation • The company reaffirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 15.45% for its ordinary shares as at 31 March 2026.

Overall, SIMCERE PHARMA’s capital base and free-float status were steady through March, with forthcoming equity issuance capacity residing mainly in its RSU programme.